Parkin is an E3 ubiquitin ligase encoded by the PRKN gene (also known as PARK2) that plays a central role in mitophagy — the selective degradation of damaged mitochondria. Parkin is one of the most significant Parkinson's disease genes, with autosomal recessive mutations causing early-onset familial PD.
Parkin is a member of the RBR (RING-in-between-RING) family of E3 ubiquitin ligases. Under basal conditions, Parkin is cytosolic and autoinhibited. Upon mitochondrial damage, Parkin is recruited to the outer mitochondrial membrane where it ubiquitinates numerous substrates, promoting mitochondrial clearance through the autophagy-lysosome pathway.
¶ Structure and Mechanism
¶ Domain Architecture
Parkin contains multiple functional domains:
- N-terminal Ubl domain: Ubiquitin-like domain that keeps Parkin inactive in the cytosol
- RING0 domain: Unique to Parkin, contains an inhibitory helix
- RING1 domain: Catalytic RING finger that accepts ubiquitin from E2
- In-between-RING (IBR) domain: Intermediate domain
- RING2 domain: Second catalytic RING finger
Parkin activation follows a carefully regulated sequence:
- Phosphorylation: PINK1 phosphorylates both ubiquitin and the Ubl domain of Parkin
- Conformational change: Phosphorylation releases autoinhibition, opening the active site
- Mitochondrial recruitment: Activated Parkin translocates to damaged mitochondria
- Ubiquitination: Parkin ubiquitinates mitochondrial outer membrane proteins
This activation cascade ensures that mitophagy only occurs when mitochondria are genuinely damaged.
- Autosomal recessive inheritance: Biallelic PRKN mutations cause juvenile-onset PD
- Over 200 pathogenic variants identified, including missense, nonsense, and copy number variants
- Parkin-associated PD typically has earlier onset (before age 40) and slower progression
- Heterozygous variants may act as risk factors for late-onset PD
Loss of Parkin function leads to:
- Accumulation of damaged mitochondria: Failure to clear dysfunctional mitochondria
- Increased oxidative stress: Damaged mitochondria produce excess ROS
- Energy deficit: Impaired mitochondrial function reduces ATP production
- Neuronal death: Particularly affecting dopaminergic neurons in the substantia nigra
The canonical mitophagy pathway proceeds as follows:
- Mitochondrial damage: Occurs via cellular stress, toxins, or mutations
- PINK1 stabilization: On damaged mitochondria, PINK1 accumulates on the outer membrane
- PINK1 activation: Activated PINK1 phosphorylates ubiquitin and Parkin
- Parkin recruitment: Phospho-Parkin translocates to mitochondria
- Substrate ubiquitination: Parkin ubiquitinates mitochondrial proteins
- Autophagy receptor recruitment: p62/SQSTM1, OPTN, NDP52 bind ubiquitin chains
- Phagosome formation: LC3-positive autophagosome engulfs the mitochondrion
- Lysosomal degradation: Fusion with lysosome completes mitophagy
Parkin ubiquitinates numerous mitochondrial substrates:
- Mitofusins (MFN1, MFN2): Fusion proteins, their ubiquitination prevents re-fusion
- VDAC1: Voltage-dependent anion channel
- TOMM20: Translocase of outer membrane
- MIRO1: Mitochondrial Rho GTPase
- HK2: Hexokinase II, linking metabolism to mitophagy
¶ Parkin and Other Neurodegenerative Diseases
While primarily a PD gene, Parkin may play roles in AD:
- Altered Parkin expression found in AD brain
- Parkin can degrade amyloid precursor protein (APP) fragments
- May affect tau phosphorylation through ubiquitin-dependent pathways
Parkin dysfunction has been reported in ALS:
- Mutations in PARKIN associated with some ALS cases
- Parkin loss may contribute to mitochondrial dysfunction in motor neurons
Parkin compensates for mutant huntingtin:
- Parkin overexpression reduces polyglutamine toxicity
- Parkin-mediated mitophagy helps clear damaged mitochondria in HD models
- AAV-PARKIN delivery: Viral vector-mediated PARKN gene expression
- PRKN promoter optimization: Enhancing expression in dopaminergic neurons
- Current trials exploring safety and efficacy in PD patients
- Parkin activators: Compounds that promote Parkin activation
- PINK1 activators: Upstream pathway enhancement
- Ubiquitin replacement: Enhancing general ubiquitination
- Antioxidants: Reducing oxidative stress on mitochondria
- Mitochondrial biogenesis promoters: PGC-1α activators
- Mitochondrial dynamics modulators: Fusion/fission balancers
| Year |
Finding |
Reference |
| 1998 |
PRKN mutations linked to autosomal recessive PD |
|
| 2006 |
PINK1-Parkin pathway identified in mitophagy |
|
| 2011 |
PINK1 phosphorylates Parkin to activate it |
|
| 2015 |
Parkin substrates comprehensively mapped |
|
| 2019 |
Parkin gene therapy shows promise in models |
|